KB-1064-01

Relatlimab

Background

Relatlimab, also known as BMS-986016, is a specific antibody that targets LAG3 and is derived from fully human immunoglobulin genes expressed in transgenic mice. This antibody is expressed as an immunoglobulin G4 (IgG4) type and contains a stabilizing hinge mutation (S228P). Relatlimab is the first humanized monoclonal antibody that targets LAG3 and is the most advanced in clinical development compared to other similar antibodies.

Specifications

Catalog Number:
KB-1064-01
Cell Line Name:
Relatlimab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
LAG3
Species Reactivity:
Human
Application:
FACS | FACS Blocking
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS | FACS Blocking

References

1.Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One 2014;9(11):e109080-e109080. 2. Lipson E, Gopal A, Neelapu SS, et al. Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies. J Immunother Cancer 2016;4:Suppl 1:232-232. abstract.
Please enable JavaScript in your browser to complete this form.